Standardize the prasrita dose of vasti and comparing standardize dose and conventional doses group of madhutailika vasti to see its efficacy in patients of sciatica.

Standardization of dose of Madhutailika Vasti in Gridhrasi (Sciatica) – A Randomized comparative clinical trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/075705

Enrollment

Registered

2024-10-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M472- Other spondylosis with radiculopathy

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patient having clinical presentation of sciatica and gridhrasi & Patient fit for vasti

Exclusion criteria

Exclusion criteria: 1) Inflammatory and malignant condition 2) Severe neurological deficit 3) H/o Ischemic heart disease and cardiac ailments 4) Diabetes mellitus 5) major systemic diseases 6) Deformities and congenital defect 7) Fracture And trauma 8) Autoimmune disorders 9) Post operative spinal cases

Design outcomes

Primary

Measure	Time frame
Standardizing the aatur hasta pramana dose of vastiTimepoint: The Standardized aatura hasta dose of primary outcome will be assessed after sample size calculation (26 weeks)	—

Secondary

Measure	Time frame
improvement & changes present in sciatica symptoms with aatur hasta pramsna dose of vasti.Timepoint: assessed at final outcome to determine effects of interventional study.(52 weeks)	—

Countries

India

Contacts

Public ContactDr Gaurav Munjal

Shri Krishna AYUSH University Kurukshetra

drashishhmehta@gmail.com8950375285

Outcome results